UK NICE Processes Not Fit For Orphan Drugs, Says New Report

 
• By Francesca Bruce
PoundSterlingPills
A report has criticized how NICE assesses orphan drug cost effectiveness • Source: Shutterstock

More from Health Technology Assessment

More from Market Access